News & Analysis as of

Personalized Medicine

Foley & Lardner LLP

Personalizing Cancer Therapy For Complex Molecular Blueprints: Insights from the I-PREDICT Trial

Foley & Lardner LLP on

One of the persistent challenges in precision oncology is the fact that most advanced cancers are complex and highly individualized. A recent study published by Jason K. Sicklick, MD and colleagues (J. Clinical Oncology)...more

Loeb & Loeb LLP

Tailored Just for You: Health & Wellness Trends for 2026

Loeb & Loeb LLP on

As we round out 2025 and rapidly approach 2026, we are watching these five trends in the health and wellness industry, which we expect will continue to drive consumer demand and raise notable legal considerations. We plan to...more

Troutman Pepper Locke

Early-Stage Spotlight - Kyha's Approach to Women's Health — PE Pathways Podcast

Troutman Pepper Locke on

In this episode of PE Pathways, Stephen Fox, a member of the health care and life science transactional team, sits down with Chelsea May, CEO and co-founder of Kyha, one of our innovative SEED™ clients from the Emerging...more

Ropes & Gray LLP

FDA Outlines “Plausible Mechanism” Approval Pathway for Personalized Therapies, But Significant Questions Remain

Ropes & Gray LLP on

FDA Commissioner Martin Makary and Center for Biologics Evaluation and Research Director Vinay Prasad recently published an article in the New England Journal of Medicine (“NEJM”) outlining the guiding principles of a new...more

Katten Muchin Rosenman LLP

Unlocking Bespoke Product Approvals: FDA Puts Forth Plausible Mechanism Pathway

On November 12, 2025, the New England Journal of Medicine published an article authored by FDA Commissioner Marty Makary and Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad introducing the concept of...more

Knobbe Martens

AI and the Fight Against Antimicrobial Resistance

Knobbe Martens on

Antimicrobial resistance has become a major concern in recent years. According to studies, approximately 1.1 million deaths each year are linked to bacterial resistance to antimicrobial drugs. The fear of antibiotic...more

Foley & Lardner LLP

From Rare Genes to Precision Health: $80M in New NIH Funding to Study Longer, Healthier Lives

Foley & Lardner LLP on

The Long Life Family Study (LLFS) is a multi-decade, multicenter research program designed to uncover the genetic and biological factors that contribute to exceptional human longevity and healthy aging. First launched in the...more

Wilson Sonsini Goodrich & Rosati

[Event] Biotech Summit 2025 - October 22nd - 23rd, Boston, MA

Wilson Sonsini’s 2nd Annual Biotech Summit will address topics of critical importance to biotech and biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more

Foley & Lardner LLP

Rethinking University Research: Innovating the Innovation Ecosystem to Support Life Sciences and Personalized Medicine

Foley & Lardner LLP on

Personalized medicine—tailoring treatments to individual patients based on their genetic makeup, lifestyle, and environment—is transforming healthcare. But this revolution didn’t begin in the private sector. It was sparked...more

WilmerHale

Amgen Hasn’t Resolved Questions on AI Medical Invention Patents

WilmerHale on

Personalized medical intervention is in a transformative phase as artificial intelligence algorithms are increasingly deployed to tailor treatments for individual patients based on their unique characteristics. Developers...more

Benesch

Pulse on AI + Healthcare: An Introduction to Healthcare AI Innovation in an Evolving Regulatory Landscape

Benesch on

The expansion of artificial intelligence (“AI”) applications in healthcare (“Healthcare AI”) has made recent headlines, from the transformation of clinical diagnostics with increased accuracy, to use of personalized medicine...more

Foley & Lardner LLP

The Rise of GenAI in Personalized Medicine and Beyond

Foley & Lardner LLP on

GenAI, or Generative AI, has seen a surge in patenting activity with China leading the way in filing patent applications for this technology. The landscape analysis by WIPO reveals Tencent, Ping An Insurance Group, and Baidu...more

Foley & Lardner LLP

Global Growth In GenAI Patenting Activity

Foley & Lardner LLP on

Between 2014-2023, China has filed more patent applications (38,000) covering Generative AI (GenAI) technology than another other country, six times more than second place United States, as reported by the World Intellectual...more

BCLP

What is FemTech and How Can It Meet the Privacy Needs of Its Users?

BCLP on

In part one of our series "FemTech: how this growing industry can build trust, protect privacy and redress healthcare inequity… one app at a time", we take an introductory look at the industry, and offer some...more

Knobbe Martens

The FDA Approves Two New Gene Therapies for the Treatment of Sickle Cell Disease

Knobbe Martens on

On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved two new gene therapies for the treatment of sickle cell disease. The first, Casgevy™ (exagamglogene autotemcel (exa-cel)), is the first-ever approved...more

American Conference Institute (ACI)

[Event] 21st Annual Life Sciences IP Summit - September 27th - 28th, Munich, Germany

Hosted by C5 Group, the 21st Annual Life Sciences IP Summit returns for another exciting year with curated programming with speakers from the pharma, biotech and medical device industries that will provide practical insights...more

Dinsmore & Shohl LLP

Medical Marijuana Will Soon be Legal in Kentucky

Dinsmore & Shohl LLP on

On March 31, 2023, Governor Andy Beshear signed Senate Bill 47 making medical marijuana use and sale legal in Kentucky, effective January 1, 2025. Kentucky now joins at least 37 other states that have legalized medical...more

Foley & Lardner LLP

Personalized Medicine at FDA: The Scope & Significance of Progress in 2022

Foley & Lardner LLP on

The Personalized Medicine Coalition (PMC) recently released its annual report on the progress of precision medicine as measured by precision medicine FDA approvals in 2022 (“Report”). As summarized in the Report, 2022...more

Foley & Lardner LLP

The Health AI Frontier: New Opportunities for Innovation Across the Health Care Sector

Foley & Lardner LLP on

With the health care industry under pressure to improve patient outcomes while controlling costs, artificial intelligence (AI) and machine learning (ML) are quickly becoming indispensable tools. These technologies show...more

Hogan Lovells

JPM2023 Trendspotting: investment insights for Innovative Medicines

Hogan Lovells on

As the industry readies itself for the January 2023 pilgrimage to the J.P. Morgan Healthcare Conference (JPM) and Biotech Showcase in San Francisco, our market-leading life sciences and health care industry team has prepared...more

Foley & Lardner LLP

USPTO Extends Patents 4 Patients Program

Foley & Lardner LLP on

Precision or personalized medicine seeks to find the right treatment for each patient at the right time based on the patient’s genes, proteins and other personal characteristics. The approach has been successfully used to...more

Foley & Lardner LLP

Personalized Medicine: 2021 FDA Guideposts for Progress – Focus On Diagnostics

Foley & Lardner LLP on

Last week I reported on The Personalized Medicine Coalition’s (PMC) recently released PERSONALIZED MEDICINE AT FDA: The Scope & Significance of Progress in 2021(2021 Report) that surveyed U.S. Food and Drug Administration...more

Foley & Lardner LLP

Personalized Medicine: 2021 FDA Guideposts for Progress

Foley & Lardner LLP on

The Personalized Medicine Coalition (PMC) released PERSONALIZED MEDICINE AT FDA: The Scope & Significance of Progress in 2021(2021 Report), its recent survey of U.S. Food and Drug Administration (FDA)-approved personalized...more

Rivkin Radler LLP

FDA Announces Digital Health Center of Excellence

Rivkin Radler LLP on

On September 22, the U.S. Food and Drug Administration (FDA) announced the launch of its Digital Health Center of Excellence within the Center for Devices and Radiological Health. The FDA called this an important step toward...more

Womble Bond Dickinson

New blood test to guide personalized cancer treatment

Womble Bond Dickinson on

On August 26, 2020, the U.S. Food and Drug Administration approved Foundation Medicine, Inc.’s Foundation One® Liquid CDx, a quantitative next-generation sequencing (NGS) test that can detect mutations using circulating...more

141 Results
 / 
View per page
Page: of 6

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide